Search

Learn about how the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) could provide a new option for patients with metastatic renal cell carcinoma.

… Monday, April 16, 2018 Summary The combination of two immunotherapies outperformed a targeted therapy with regard to overall survival in a phase III study of untreated patients with metastatic renal cell carcinoma (a type of kidney cancer ). Update: On April 16, 2018, the FDA approved the combination

Two studies on multiple myeloma provide new information about diagnosing and treating this blood cancer.

… Monday, December 9, 2019 Summary One study looked at a new drug combination for this blood cancer; the other focused on genetic markers linked to how the disease progresses. Multiple myeloma is a cancer that arises from the type of white blood cells called plasma cells. When normal plasma cells in the

Sloan Kettering Institute investigators have found that a subpopulation of cells within a type of sarcoma called malignant peripheral nerve sheath tumor appear to be similar to a type of neural stem cells.

… Monday, June 14, 2021 Neurofibromatosis type 1 (NF1) is the most common hereditary disease of the nervous system. Overall, it is a rare condition that affects about one in 3,000 people in the United States and worldwide. It is characterized by tumors that grow along the peripheral nerves (the nerves

Patients with secondary rectal cancer after radiotherapy for prostate cancer have shorter survival compared with matched treatment-naïve patients. However, a new study by investigators at MSK has found distinct differences in patient characteristics, available treatment options, and tumor biologic characteristics that may explain the gap.

… Tuesday, April 29, 2025 Patients with secondary rectal cancer (SRC) after radiotherapy (RT) for prostate cancer have shorter survival compared with matched treatment-naïve patients,  (1) but factors explaining this gap have been unclear. Now, a new study by investigators at Memorial Sloan Kettering Cancer

Learn about Anna-Katerina “Kat” Hadjantonakis, who is Chair of the Sloan Kettering Institute’s Developmental Biology Program.

… Monday, December 30, 2019 Earlier this year, Anna-Katerina “Kat” Hadjantonakis was named Chair of the Sloan Kettering Institute ’s Developmental Biology Program. She succeeded Kathryn Anderson , who had led the program since it launched in 2003. We spoke with Dr. Hadjantonakis about the field of developmental

Samuel Singer has been appointed Chief of the Gastric and Mixed Tumor Service in the Department of Surgery.

… Monday, February 1, 2010 Summary Samuel Singer has been appointed Chief of the Gastric and Mixed Tumor Service in the Department of Surgery. Samuel Singer has been appointed Chief of the Gastric and Mixed Tumor Service in the Department of Surgery. Dr. Singer is a surgical oncologist and leader of Memorial

There are more than 100 subtypes of brain tumors, making them a challenge to accurately diagnose. Now researchers have figured out a way to reliably distinguish them.

… Wednesday, March 14, 2018 Summary Proper diagnosis and classification is vital for brain tumors , but until now it hasn’t been easy. This week an international team of investigators is reporting a new way to distinguish among the 100-plus different subtypes of the disease. There are more than 100 subtypes

A generous gift provides a major boost to translational research at MSK.

… Friday, January 1, 2021 Dear MSK Community, Breakthrough cancer discovery can start anywhere: a patient with a unique case, a researcher with a hunch, or an unexpected result that connects seemingly disparate findings. An investigation into a new treatment can begin with the patient, move to the lab,

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.

… Wednesday, November 17, 2010 An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma , the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of

Learn more about entrectinib, a targeted therapy being evaluated in patients with solid tumors.

… Wednesday, April 5, 2017 Summary Entrectinib is a targeted therapy that passed safety and tolerability standards in patients with solid tumors in two phase I trials. Now, the drug will be tested in a phase II trial. At last year’s annual meeting of the American Association for Cancer Research (AACR),